Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.64 |
| ▸ | AURKA | O14965 | 9/20 | 0.54 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.54 |
| ▸ | CDK1 | P06493 | 1/20 | 0.52 |
| ▸ | CDK2 | P24941 | 1/20 | 0.52 |
| ▸ | MAPT | P10636 | 2/20 | 0.51 |
| ▸ | TP53 | P04637 | 1/20 | 0.51 |
| ▸ | FLT3 | P36888 | 9/20 | 0.50 |
| ▸ | KDR | P35968 | 7/20 | 0.49 |
| ▸ | FLT1 | P17948 | 3/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.48 |
| ▸ | ACR | P10323 | 1/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | TSHR | P16473 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8287822 | 0.86 | POLB (0.56) | POLBMAPTTP53FLT3KMT2A | |
| SCHEMBL4552859 | 0.82 | CDK1 (0.57) | AURKAAURKBCDK1CDK2FLT3 | |
| SCHEMBL8287820 | 0.81 | BCHE (0.54) | POLBMAPTTP53FLT3LMNA | |
| SCHEMBL69842 | 0.81 | KMT2A (0.64) | POLBMAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL8290060 | 0.79 | SMN1; SMN2 (0.56) | POLBMAPTLMNASMN1; SMN2KMT2A | |
| SCHEMBL29114951 | 0.78 | KMT2A (0.60) | POLBMAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL1726857 | 0.77 | LMNA (0.76) | POLBMAPTTP53LMNASMN1; SMN2 | |
| SCHEMBL30988464 | 0.76 | KMT2A (0.57) | POLBCDK2MAPTTP53LMNA | |
| SCHEMBL29452680 | 0.76 | KMT2A (0.57) | POLBCDK2MAPTTP53LMNA | |
| SCHEMBL13028559 | 0.75 | LMNA (0.73) | POLBMAPTTP53LMNASMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | A*BIO PTE LTD. (SG) | 2007-07-19 | — | — | US | disclosed |
| WO-2005040161-A1 | BIARYL LINKED HYDROXAMATES: PREPARATION AND PHARMACEUTICAL APPLICATIONS | S*BIO PTE LTD (SG) | 2005-05-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070167499-A1 | Biaryl linked hydroxamates: preparation and pharmaceutical applications | HDAC1, HDAC11, HDAC2 | POLB 525/4885AURKA 605/4885AURKB 275/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.